Výsledky vyhledávání - "Poliana Patah"

Akademický článek

Hematopoietic stem cell transplantation for Hodgkin's disease

Autor: Poliana Patah, Luis Fayad, Marcos de Lima

Publikováno v: Revista Brasileira de Hematologia e Hemoterapia, Vol 33, Iss 1, Pp 4-5 (2011)

Externí odkaz: https://doaj.org/article/801cf8d730c24d1c9ec083f7a8ca5a2a

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Autor: Jason Westin, Alejandro Martín García-Sancho, Marc Hoffmann, Theodoros P. Vassilakopoulos, Su-Peng Yeh, Argyrios Gkasiamis, Poliana Patah, Arpankumar Patel, Ju Li, Grzegorz S. Nowakowski

Publikováno v: Blood. 140:9475-9477

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e5e95cacc0a89276dc9ec3b2b360cefe
https://doi.org/10.1182/blood-2022-162774

Zobrazit plný text záznamu

ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study

Autor: Julio C. Chavez, Jean-Marie Michot, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo, John Kuruvilla, Antonio Pinto, Vincent Ribrag, Emmanuel Bachy, Tonia J. Buchholz, Soraya Carrancio, Wen-Chi Chou, Carla Guarinos, Fan Wu, Shaoyi Li, Poliana Patah, Michael Pourdehnad, Loretta Nastoupil

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S377-S378

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b4521ff9625b9b2c1e5a88f806fba59
https://doi.org/10.1016/s2152-2650(22)01538-5

Zobrazit plný text záznamu

Poster: ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S165

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6e339f66cf8e4ceeb3e9b562e3afecbc
https://doi.org/10.1016/s2152-2650(22)01009-6

Zobrazit plný text záznamu

A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS

Autor: Silvia Ferrari, Antonio Pinto, Kasibhatla Shailaja, F. Wu, Cecilia Carpio, Tatyana Feldman, L. J. Nastoupil, Michael Pourdehnad, Soraya Carrancio, Emmanuel Bachy, Carla Guarinos, Julio C. Chavez, Poliana Patah, D. Morillo, S. Li, J-M. Michot, Tonia J. Buchholz, John Kuruvilla

Publikováno v: Hematological Oncology. 39

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::271669edcfb7f2b7a4ebd04d37c0c04a
https://doi.org/10.1002/hon.89_2881

Zobrazit plný text záznamu

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Autor: Soraya Carrancio, Daniel Morillo, Cecilia Carpio, Tatyana Feldman, Shaoyi Li, Michael Pourdehnad, Poliana Patah, Julio C. Chavez, Emmanuel Bachy, Carla Guarinos, Antonio Pinto, Fan Wu, Jean-Marie Michot, Loretta J. Nastoupil, John Kuruvilla, Tonia J. Buchholz, Silvia Ferrari, Vincent Ribrag

Publikováno v: Blood. 138:3574-3574

CC-99282 is a novel, small molecule CELMoD ® agent that co-opts cereblon to induce targeted degradation of Ikaros/Aiolos, transcription factors critical for development of B-cell malignancies. Lopez-Girona et al. reported that in preclinical models,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2311d150957c8cbbeaa909badde00343
https://doi.org/10.1182/blood-2021-147333

Zobrazit plný text záznamu

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial

Publikováno v: JAMA oncology. 6(1)

Importance Multiple immunostimulatory agonist antibodies have been clinically tested in solid tumors to evaluate the role of targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor–related protein in anticancer treatments. Objective T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbf6e00e12ab72c627594264db08d14e
https://pubmed.ncbi.nlm.nih.gov/31697308

Zobrazit plný text záznamu

25-OR: Mismatches at the low-expression (LEL) HLA class II loci, MICA and the NOD2/CARD15 genotype determine poor outcome in bone marrow transplantation

Autor: Marcelo Fernandez-Vina, Mei Han, Susana Pesoa, Marcos de Lima, Pedro Cano, Poliana Patah, Ping Liu, Yizhou Zou, Richard Champlin, Peter Stastny

Publikováno v: Human Immunology. 68:S113

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a027cd1ee18ddf6bdf559a1099368ad2
https://doi.org/10.1016/j.humimm.2007.08.218

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání